Qiagen N V Net Income per Employee (QGEN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Qiagen N v   (NYSE: QGEN)
 

Qiagen N V Net Income per Employee

QGEN's Quarterly Results, Trends, Rankings, Statistics
With an income increase of 408.28% in the fourth quarter 2025, year on year to cumulative value of $425 million, and with 5,700 employees, Qiagen N V 's income per employee grew on trailing twelve month basis to $ 74,540. The income per employee at Qiagen N V ' was above the company average.
The Healthcare sector has seen employees of 22 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 1286, from total ranking in previous quarter at 1913.


What is Income per Employee Ratio?






QGEN Net Income per Employee (Dec 31 2025)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2024)
IV. Quarter
Y / Y Net Income Change 408.28 % - - - -75.51 %
Net Income per Employee (TTM) $ 74,540 14,665 14,665 14,665 14,665
QGEN's Total Ranking # 1286 # 1913 # # #
Seq. Net Income Change - - - - -


QGEN Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 120
Overall Market # 1286

Net Income per Employee Statistics
High Average Low
$ 89,930 $ 38,929 $ -7,273
(Dec 31 2021)   (Dec 31 2019)




  News about Qiagen N v Income per employee

QIAGEN N.V. announces successful placement of new net share settled convertible bonds



QIAGEN N.V. Successfully Places Innovative Net Share Settled Convertible Bonds: A Strategic Move Amidst Global Market Dynamics
In a strategic development reflecting both confidence and adaptability in fluctuating global markets, QIAGEN N.V. has recently announced the successful placement of new net share settled convertible bonds. This financial maneuver signifies the company’s commitment to expanding its capital base while embracing innovative financing solutions.
Convertible bonds, particularly those that are net share settled, allow companies to leverage existing equity while giving investors the option to convert their bonds into shares. This can be a strategic instrument for capital management, enabling QIAGEN to raise funds while retaining flexibility. Investors are typically attracted to convertible bonds due to the potential upside they offer; they can enjoy fixed-income security with the opportunity to convert to equity and participate in the companyns growth.
This placement comes at a pivotal time as QIAGEN continues to assert itself in the competitive landscape of biomolecular technology. The biotechnology sector is characterized by rapid innovation and a constant need for investment in research and development. Such financing strategies not only bolster a firm’s operational capacity but also send a strong positive signal to investors regarding the companyns financial health.





Companies with similar Income per Employee for 12 month ending Dec 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2025Number of Employees Dec 31 2025
Carlisle Companies Incorporated  125,542.37 $ 740.700  Million 5,900 
Alnylam Pharmaceuticals Inc   125,498.80 $ 313.747  Million 2,500 
Astrazeneca Plc  123,140.79 $ 10,233.000  Million 83,100 
Alkermes Plc   117,884.88 $ 241.664  Million 2,050 
Soleno Therapeutics Inc  114,780.22 $ 20.890  Million 182 
Inspire Medical Systems inc   109,093.77 $ 145.422  Million 1,333 
Check Cap Ltd  108,947.37 $ 4.140  Million 38 
Biomarin Pharmaceutical Inc  108,320.71 $ 348.901  Million 3,221 
Pfizer Inc  104,160.00 $ 7,812.000  Million 75,000 
Bio rad Laboratories Inc   102,000.00 $ 759.900  Million 7,450 
Idexx Laboratories Inc  96,314.91 $ 1,059.464  Million 11,000 
Cryoport inc   95,258.81 $ 70.301  Million 738 
Globus Medical Inc   89,644.67 $ 537.868  Million 6,000 
Lemaitre Vascular Inc   88,143.51 $ 57.734  Million 655 
Veracyte Inc   87,884.77 $ 66.353  Million 755 
Seres Therapeutics Inc   86,303.03 $ 5.696  Million 66 
Waters Corporation  81,345.44 $ 642.629  Million 7,900 
Ani Pharmaceuticals Inc  80,759.79 $ 78.337  Million 970 
Solventum Corporation  77,800.00 $ 1,556.000  Million 20,000 
Hologic Inc  76,916.55 $ 543.800  Million 7,070 
Embecta Corp   75,405.41 $ 139.500  Million 1,850 
Dexcom Inc   75,342.34 $ 836.300  Million 11,100 
Qiagen N v   74,540.35 $ 424.880  Million 5,700 
Abbvie Inc   74,263.16 $ 4,233.000  Million 57,000 
Medpace Holdings Inc   72,761.77 $ 451.123  Million 6,200 
Agilent Technologies inc   71,270.72 $ 1,290.000  Million 18,100 
Strata Critical Medical Inc   68,797.00 $ 41.347  Million 601 
Progyny Inc   68,364.49 $ 58.520  Million 856 
Edwards Lifesciences Corporation  66,837.50 $ 1,069.400  Million 16,000 
Alpha Pro Tech Ltd   66,666.67 $ 8.200  Million 123 


Date modified: 2026-07-07T12:43:35+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.